ASH 2019 | Ixazomib or lenalidomide post-ASCT in NDMM
Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, discusses a phase II study (NCT02253316) analyzing the safety and efficacy of using lenalidomide and ixazomib as part of maintenance therapy after autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (MM). Results indicate that ixazomib and lenalidomide maintenance are well tolerated. Regarding efficacy, Prof. Vij reveals the study was not able to show that ixazomib is not inferior to lenalidomide. However, Prof. Vij believes this study will continue to produce meaningful results, as it will show what the utility of ixazomib is for patients who cannot tolerate lenalidomide. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
